Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 2,913 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Event Clear all

Conditions: Neurofibromatosis 1, Neurofibroma, Plexiform
Interventions: Medication Event Monitoring System (MEMS^TM), Questionnaires; Behavioral · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 3 Years to 59 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Dry Needling
Interventions: Delphi Questionaire; Other
Lead sponsor: Youngstown State University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Youngstown, Ohio

Conditions: Breast Cancer
Interventions: Poziotinib; Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 35
States / cities: Huntsville, Alabama • Anaheim, California • Greenbrae, California + 31 more

Conditions: Cancer
Interventions: La Roche Posay Lipikar Wash Atopy-Prone Plus (AP+) Moisturizing Face and Body Wash, La Roche Posay Lipikar AP+ Triple Repair Moisturizing Cream, La Roche Posay Cicaplast balm Panthenol/Vitamin B5 (B5+); Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions: Percutaneous coronary intervention; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 30,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Suicidal Ideation, Suicide, Attempted, Coping Skills, Depression, Anxiety, PTSD
Interventions: Group Brief Cognitive-Behavioral Therapy (G-BCBT), Dialectical Behavior Therapy (DBT) Skills Group; Behavioral
Lead sponsor: University of North Carolina, Charlotte; Other
Eligibility: 18 Years to 99 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Portsmouth, Virginia

Conditions: Cancer
Interventions: "We Want to Know" campaign, Patient survey at 2 time points; Other
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 21 Years to 80 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 2
States / cities: Atlanta, Georgia • Seattle, Washington

Conditions: Cardiovascular Diseases+Liver Transplantation
Interventions: Cardiopulmonary exercise testing; Device
Lead sponsor: Andres Duarte-Rojo; Other
Eligibility: 45 Years to 75 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Phoenix, Arizona • Pittsburgh, Pennsylvania

Conditions: Breast Cancer, Triple Negative Breast Cancer
Interventions: Talazoparib, Atezolizumab, Radiation; Drug · Radiation
Lead sponsor: Mylin A. Torres, MD; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Birmingham, Alabama • Atlanta, Georgia

Conditions: Chronic Pain
Interventions: Mindfulness Meditation, Therapeutic Hypnosis, Story Listening; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 60 Years and older
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Diabetes Type II
Interventions: Low Carbohydrate Diet, American Diabetes Association Diet, Mindfulness and Positive Affect Skills; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Polyp Colorectal, Rectal Adenoma, Adenoma Colon Polyp
Interventions: Not listed
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Heart Disease, Cardiovascular Disease, Sedentary Lifestyle, Overweight, Obesity
Interventions: Strong Hearts, Healthy Communities, Strong Hearts, Healthy Women; Behavioral
Lead sponsor: Cornell University; Other
Eligibility: 40 Years and older · Female only
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 16
States / cities: Broadus, Montana • Chinook, Montana • Choteau, Montana + 13 more

Conditions: HIV Infection
Interventions: Positive STEPS; Behavioral
Lead sponsor: Fenway Community Health; Other
Eligibility: 13 Years to 24 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Generalized Anxiety Disorder
Interventions: Cariprazine 0.75 mg/day, Cariprazine 1.5 mg/day, Cariprazine 3.0 mg/day, Placebo; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 36
States / cities: Little Rock, Arkansas • Colton, California • Costa Mesa, California + 29 more

Conditions: Growth & Development
Interventions: PALS and, BEECH, Control condition; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 5 Months to 35 Months
Enrollment: 260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Aortic Valve Replacement
Interventions: Subjects previously implanted with INSPIRIS RESILIA Model 11500A and are undergoing planned valve-in-valve treatment.; Diagnostic Test
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2028 – 2031
U.S. locations: 7
States / cities: Los Angeles, California • Gainesville, Florida • Orlando, Florida + 4 more

Conditions: Nutrition Disorders
Interventions: Orange Fleshed Sweet Potato (OFSP) agriculture promotion and nutrition education on vitamin A intake, Healthy Baby Toolkit, Standart of care; Behavioral
Lead sponsor: Emory University; Other
Eligibility: Not listed
Enrollment: 605 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Internet-based Intervention, Web-based Intervention, Online Intervention, Erectile Dysfunction, Telemedicine
Interventions: An automated patient-reported outcome data collection and adverse event surveillance tool; Other
Lead sponsor: Ro; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Psoriasis Vulgaris
Interventions: Polysomnography (PSG); Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Pulmonary Arterial Hypertension
Interventions: macitentan (ACT-064992), placebo; Drug
Lead sponsor: Actelion; Industry
Eligibility: 12 Years and older
Enrollment: 742 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 33
States / cities: Birmingham, Alabama • Pheonix, Arizona • Los Angeles, California + 28 more

Conditions: Acute Coronary Syndrome, Physical Inactivity
Interventions: Positive Psychology + Motivational Interviewing; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 95 Years
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prostate Cancer
Interventions: Enzalutamide, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,717 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 65
States / cities: Birmingham, Alabama • Tucson, Arizona • La Mesa, California + 34 more

Conditions: Systemic Lupus Erythematosus
Interventions: Zostavax vaccine; Drug
Lead sponsor: Oklahoma Medical Research Foundation; Other
Eligibility: 50 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Search by objective public record fields.

Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1(NF1) on Clinical Treatment Trials

Identifying Which Adverse Events Associated With Dry Needling Should be Included For Informed Consent: A Modified e-Delphi Study

Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer

Skin Changes From the Use of Moisturizers in Participants With Cancer Experiencing Dermatological Adverse Events

The xDAPT External Validation Study

The Group Risk Reduction Intervention Therapy (GRRIT) Project

Effective Communication for Preventing and Responding to Oncology Adverse Events

Usefulness of Cardiopulmonary Exercise Testing for Cardiovascular Risk Estimation and Frailty Assessment in Liver Transplant Candidates

A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer

Mechanisms of Mindfulness Meditation and Self-Hypnosis for Pain in Older Adults With Chronic Pain

A Pilot Study of the Effects of Diet and Behavioral Interventions on Health in Diabetics

GelPOINT® Path-Assisted Endoscopic Removal of Colon and Rectal Polyps: A Feasibility and Safety Study

Strong Hearts: Rural CVD Prevention

Improving Antiretroviral Medication Adherence Among HIV-infected Youth

A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone

An Integrative Approach to Improve Child Outcomes Through Research-based Parent and Teacher Interventions

INSPIRIS RESILIA Aortic Valve, Valve-in-Valve Surveillance Study

Improving Infant Nutrition in Southern Ethiopia

Evaluating Treatment Continuation in Telehealth Patients Receiving an Automated Patient-Reported Outcome Tool

Dermatologic Research Evaluation and Monitoring of Sleep in Moderate-to-Severe Psoriasis

Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension

Positive Emotions Following Acute Cardiac Events

A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer

Zostavax in Systemic Lupus Erythematosus